| Description |
Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody. Veltuzumab has low EC50 value of 0.08-0.09 μg/mL in the Daudi cell line. Veltuzumab can be used for the research of cancer including non-Hodgkin lymphoma (NHL)[1].
|
| Related Catalog |
|
| Target |
EC50: 0.08-0.09 μg/mL (in the Daudi cell line)[1]
|
| In Vitro |
Veltuzumab significantly reduces off-rates in human lymphoma cell lines, as well as increases complement-dependent cytotoxicity in 1 of 3 cell lines, but no other in vitro differences[1]. Veltuzumab (0.001-10 μg/mL, 3 h) has low EC50 value of 0.08-0.09 μg/mL in the Daudi cell line[1]. Cell Cytotoxicity Assay[1] Cell Line: 4 lymphoma cell lines (SU-DHL-6, Daudi, Raji and WSU-FSCCL) Concentration: 5 μg/mL Incubation Time: 4 days Result: Had the sensitivity correlated with CD20 expression (SU-DHL6> Raji > Daudi > WSU-FSCCL).
|
| In Vivo |
Veltuzumab (i.v. or s.c.; 5, 20 and 60 μg; single) can control tumor growth or deplete circulating or sessile B cells at low doses in mouse models of intraperitoneal and subcutaneous doses[1]. Veltuzumab (i.p.; 0.05-35 μg) are significantly effective in vivo[1]. Animal Model: Lymphoma xenograft model[1] Dosage: 5, 20 and 60 μg Administration: intraperitoneal and subcutaneous, single Result: Showed low dose of 0.05 μg increased the MST. Animal Model: SCID mice[1] Dosage: 0.5, 0.25, 0.1, or 0.05 μg; 35, 3.5, 0.35, or 0.035 μg Administration: intraperitoneal, single Result: Improved significantly survival.
|
| References |
[1]. David M Goldenberg, et al. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood
|
